Research analysts at HC Wainwright boosted their Q1 2025 earnings per share (EPS) estimates for shares of Allogene ...

Equities researchers at HC Wainwright issued their Q1 2025 EPS estimates for LENZ Therapeutics in a note issued to investors ...

Lyell Immunopharma’s (LYEL) jumped over 8% on Friday as investors’ interest surged. Despite posting unimpressive Q4 results a ...

Fintel reports that on March 21, 2025, HC Wainwright & Co. downgraded their outlook for OptiNose (NasdaqGS:OPTN) from Buy to ...

H.C. Wainwright analyst Yi Chen reiterated a Buy rating on Barinthus Biotherapeutics (BRNS – Research Report) today and set a price target of ...

SAN FRANCISCO, March 20, 2025 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR ) today announced that the company will be webcasting its participation in the H.C. Wainwright 3rd Annual Autoimmune & ...

About VYNE Therapeutics Inc. VYNE is a clinical-stage biopharmaceutical company focused on developing differentiated therapies to treat chronic inflammatory and immune-mediated conditions with high ...

HC Wainwright initiated coverage on Alpha Cognition, noting a new twist on a tried-and-tested treatment paradigm.

Fintel reports that on March 17, 2025, HC Wainwright & Co. initiated coverage of Actuate Therapeutics (NasdaqGM:ACTU) with a ...